Future Directions

  • Michael Kinter
  • Caroline S. Kinter
Part of the SpringerBriefs in Systems Biology book series (BRIEFSBIOSYS)


The future directions for the targeted quantitative proteomics experiment should address a small number of current problems and incorporate new developments in mass spectrometry instrumentation. Two notable problems at this time are the broader acceptance of selected reaction monitoring as a primary method of protein quantitation and at least some improvement in the sensitivity of the analysis. Improvements will always include the continuing evolution of the instruments to have higher resolution, faster scan rates, and better sensitivity. Others improvements will be seen in continued development of the peptide mass spectrometry databases. Progress in each of these areas is inevitable. The most difficult area to predict is the potential for new chemical tools. For example, reagents that improve sample processing or increase the sensitivity of selected classes of peptides can also have a major impact.


Select Reaction Monitoring Quantitative Proteomics Protein Quantitation Immunochemical Method Mass Spectroscopist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Barnidge DR, Goodmanson MK, Klee GG, Muddiman DC (2004) Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution mass spectrometry. J Proteome Res 3:644–652PubMedCrossRefGoogle Scholar
  2. 2.
    Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, Sabatine MS, Gerszten RE, Carr SA (2009) Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem 55:1108–1117PubMedCrossRefGoogle Scholar
  3. 3.
    Hoofnagle AN, Becker JO, Wener MH, Heinecke JW (2008) Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem 54:1796–1804PubMedCrossRefGoogle Scholar
  4. 4.
    Whiteaker JR, Lin C, Kennedy J, Hou L, Trute M, Sokal I, Yan P, Schoenherr RM, Zhao L, Voytovich UJ, Kelly-Spratt KS, Krasnoselsky A, Gafken PR, Hogan JM, Jones LA, Wang P, Amon L, Chodosh LA, Nelson PS, McIntosh MW, Kemp CJ, Paulovich AG (2011) A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol 29:625–634PubMedCrossRefGoogle Scholar
  5. 5.
    Kinter M (2004) Toward broader inclusion of liquid chromatography-mass spectrometry in the clinical laboratory. Clin Chem 50:1500–1502PubMedCrossRefGoogle Scholar
  6. 6.
    Rodriguez H, Tezak Z, Mesri M, Carr SA, Liebler DC, Fisher SJ, Tempst P, Hiltke T, Kessler LG, Kinsinger CR, Philip R, Ransohoff DF, Skates SJ, Regnier FE, Anderson NL, Mansfield E, Workshop Participants (2010) Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. Clin Chem 56:237–243PubMedCrossRefGoogle Scholar
  7. 7.
    Regnier FE, Skates SJ, Mesri M, Rodriguez H, Tezak Z, Kondratovich MV, Alterman MA, Levin JD, Roscoe D, Reilly E, Callaghan J, Kelm K, Brown D, Philip R, Carr SA, Liebler DC, Fisher SJ, Tempst P, Hiltke T, Kessler LG, Kinsinger CR, Ransohoff DF, Mansfield E, Anderson NL (2010) Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. Clin Chem 56:165–171PubMedCrossRefGoogle Scholar
  8. 8.
    Picotti P, Lam H, Campbell D, Deutsch EW, Mirzaei H, Ranish J, Domon B, Aebersold R (2008) A database of mass spectrometric assays for the yeast proteome. Nat Methods 5:913–914PubMedCrossRefGoogle Scholar
  9. 9.
    Hüttenhain R, Surinova S, Ossola R, Sun Z, Campbell D, Cerciello F, Schiess R, Bausch-Fluck D, Rosenberger G, Chen J, Rinner O, Kusebauch U, Hajdúch M, Moritz RL, Wollscheid B, Aebersold R (2013) N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications. Mol Cell Proteomics 12:1005–1016PubMedCrossRefGoogle Scholar
  10. 10.
    Peterson AC, Russell JD, Bailey DJ, Westphall MS, Coon JJ (2012) Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol Cell Proteomics 11:1475–1488PubMedCrossRefGoogle Scholar
  11. 11.
    Frahm JL, Bori ID, Comins DL, Hawkridge AM, Muddiman DC (2007) Achieving augmented limits of detection for peptides with hydrophobic alkyl tags. Anal Chem 79:3989–3995PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Michael Kinter
    • 1
  • Caroline S. Kinter
    • 1
  1. 1.Oklahoma Medical Research FoundationOklahoma CityUSA

Personalised recommendations